PSPavla Stepankova

Pavla Stepankova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pavla Stepankova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Heidi Mocikova

    Department of Hematology, Fakultni nemocnice Kralovske Vinohrady and 3rd Faculty of Medicine, Charles University, Prague, Czech Republic

    1 shared publication
  • Jan Koren

    First Medical Department - Clinical Department of Hematooncology, First Faculty of Medicine and General Teaching Hospital, Charles University in Prague, Prague

    1 shared publication
  • Jana Markova

    Department of Internal Medicine-Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic

    1 shared publication
  • Jozef Michalka

    Department of Internal Medicine, Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Czech Republic

    1 shared publication
  • Lucie Buresova

    Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic

    1 shared publication
  • Ludek Raida

    Department of Hemato-Oncology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    1 shared publication

Latest Publications

  • Open Access

    Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

    by Heidi Mocikova, Robert Pytlik, Pavla Stepankova, Jozef Michalka, Jana Markova, Jan Koren, Lucie Buresova, Ludek Raida, Zdenek Kral

    Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.